{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:52:14Z","timestamp":1781761934635,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13555-026-01788-w","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:14:12Z","timestamp":1780575252000},"page":"3555-3575","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost\u2013Effectiveness Analysis of Bimekizumab against Interleukin-23 Inhibitors in Patients with Plaque Psoriasis in Japan"],"prefix":"10.1007","volume":"16","author":[{"given":"Atsuyuki","family":"Igarashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0519-0925","authenticated-orcid":false,"given":"Koichi","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8771-7504","authenticated-orcid":false,"given":"Yukihiko","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiko","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Hase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"1","key":"1788_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/abd1806-4841.20153038","volume":"90","author":"MF Oliveira","year":"2015","unstructured":"Oliveira MF, Rocha BO, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9\u201320.","journal-title":"An Bras Dermatol"},{"issue":"3","key":"1788_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7861\/clinmed.2021-0257","volume":"21","author":"A Raharja","year":"2021","unstructured":"Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med (Lond). 2021;21(3):170\u20133.","journal-title":"Clin Med (Lond)"},{"key":"1788_CR3","doi-asserted-by":"crossref","unstructured":"Sbidian E, Chaimani A, Guelimi R, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2023;7(7):CD011535.","DOI":"10.1002\/14651858.CD011535.pub6"},{"key":"1788_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180","volume":"8","author":"G Damiani","year":"2021","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: results and insights from the Global Burden of Disease 2019 study. Front Med (Lausanne). 2021;8:743180.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"1788_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450","volume":"5","author":"K Kubota","year":"2015","unstructured":"Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5(1):e006450.","journal-title":"BMJ Open"},{"issue":"6","key":"1788_CR6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.4103\/2229-5178.193908","volume":"7","author":"R Sarkar","year":"2016","unstructured":"Sarkar R, Chugh S, Bansal S. General measures and quality of life issues in psoriasis. Indian Dermatol Online J. 2016;7(6):481\u20138.","journal-title":"Indian Dermatol Online J"},{"issue":"10","key":"1788_CR7","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/1346-8138.17424","volume":"51","author":"M Okuse","year":"2024","unstructured":"Okuse M, Soekawa M, Itakura A, et al. Perspectives of Japanese patients on psoriatic disease burden: results from \u201cPsoriasis and Beyond,\u201d the Global Psoriatic Disease Survey. J Dermatol. 2024;51(10):1298\u2013309.","journal-title":"J Dermatol"},{"issue":"4","key":"1788_CR8","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/jdv.14630","volume":"32","author":"Y Okubo","year":"2018","unstructured":"Okubo Y, Tsuruta D, Tang AC, et al. Analysis of treatment goal alignment between Japanese psoriasis patients and their paired treating physicians. J Eur Acad Dermatol Venereol. 2018;32(4):606\u201314.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1788_CR9","unstructured":"European Dermatology Forum. EuroGuiDerm guideline for the systemic treatment of psoriasis vulgaris. 2024 Mar."},{"issue":"1","key":"1788_CR10","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1080\/07853890.2021.1986637","volume":"53","author":"BI Romero","year":"2021","unstructured":"Romero BI, Dauden E, Foraster FC, Gonzalez-Cantero A, Carrascosa Carrillo JM. Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document. Ann Med. 2021;53(1):1727\u201336.","journal-title":"Ann Med"},{"issue":"6","key":"1788_CR11","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/bjd\/ljad035","volume":"188","author":"B Strober","year":"2023","unstructured":"Strober B, Tada Y, Mrowietz U, et al. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial. Br J Dermatol. 2023;188(6):749\u201359.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1788_CR12","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1007\/s13555-024-01261-6","volume":"14","author":"M Augustin","year":"2024","unstructured":"Augustin M, Gottlieb AB, Lebwohl M, et al. Complete skin clearance is associated with the greatest benefits to health-related quality of life and perceived symptoms for patients with psoriasis. Dermatol Ther (Heidelb). 2024;14(10):2841\u201357.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"1788_CR13","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/1346-8138.15803","volume":"48","author":"K Kamiya","year":"2021","unstructured":"Kamiya K, Oiso N, Kawada A, Ohtsuki M. Epidemiological survey of the psoriasis patients in the Japanese Society for Psoriasis Research from 2013 to 2018. J Dermatol. 2021;48(6):864\u201375.","journal-title":"J Dermatol"},{"issue":"8","key":"1788_CR14","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s13555-022-00760-8","volume":"12","author":"A Armstrong","year":"2022","unstructured":"Armstrong A, Fahrbach K, Leonardi C, et al. Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: a systematic literature review and a network meta-analysis. Dermatol Ther (Heidelb). 2022;12(8):1777\u201392.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1788_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2299598","volume":"35","author":"C Miyazaki","year":"2024","unstructured":"Miyazaki C, Masuda J, Rodriguez-Rey MD, et al. Real-world biologic treatment patterns and healthcare resource utilization in psoriasis patients using an insurance claims database in Japan. J Dermatolog Treat. 2024;35(1):2299598.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1788_CR16","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/1346-8138.14870","volume":"46","author":"Y Tada","year":"2019","unstructured":"Tada Y, Ishii K, Kimura J, Hanada K, Kawaguchi I. Patient preference for biologic treatments of psoriasis in Japan. J Dermatol. 2019;46(6):466\u201377.","journal-title":"J Dermatol"},{"issue":"11","key":"1788_CR17","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/1346-8138.16543","volume":"49","author":"Y Tada","year":"2022","unstructured":"Tada Y, Kim H, Spanopoulos D, et al. Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: a retrospective claims database study. J Dermatol. 2022;49(11):1106\u201317.","journal-title":"J Dermatol"},{"issue":"6","key":"1788_CR18","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/1346-8138.17234","volume":"51","author":"A Tanaka","year":"2024","unstructured":"Tanaka A, Yuasa A, Kamei K, et al. Cost-effectiveness analysis of abrocitinib compared with standard of care in adult moderate-to-severe atopic dermatitis in Japan. J Dermatol. 2024;51(6):759\u201371.","journal-title":"J Dermatol"},{"issue":"1","key":"1788_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12895-018-0074-0","volume":"18","author":"R Sruamsiri","year":"2018","unstructured":"Sruamsiri R, Iwasaki K, Tang W, Mahlich J. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database. BMC Dermatol. 2018;18(1):5.","journal-title":"BMC Dermatol"},{"issue":"2","key":"1788_CR20","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1111\/1346-8138.16691","volume":"50","author":"H Saeki","year":"2023","unstructured":"Saeki H, Mabuchi T, Asahina A, et al. English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). J Dermatol. 2023;50(2):e41\u201368.","journal-title":"J Dermatol"},{"issue":"4","key":"1788_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12946","volume":"92","author":"LL Ten Bergen","year":"2020","unstructured":"Ten Bergen LL, Petrovic A, Krogh Aarebrot A, Appel S. The TNF\/IL-23\/IL-17 axis \u2013 head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol. 2020;92(4):e12946.","journal-title":"Scand J Immunol"},{"issue":"4","key":"1788_CR22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","volume":"77","author":"S Glatt","year":"2018","unstructured":"Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"10273","key":"1788_CR23","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","volume":"397","author":"KB Gordon","year":"2021","unstructured":"Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475\u201386.","journal-title":"Lancet"},{"issue":"10273","key":"1788_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487\u201398.","journal-title":"Lancet"},{"issue":"2","key":"1788_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142\u201352.","journal-title":"N Engl J Med"},{"issue":"2","key":"1788_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","volume":"385","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130\u201341.","journal-title":"N Engl J Med"},{"key":"1788_CR27","unstructured":"Pharmaceuticals and Medical Devices Agency. List of approved drugs: April 2004 to September 2025. https:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/approved-information\/drugs\/0002.html. Accessed 7 Oct 2025."},{"key":"1788_CR28","unstructured":"Center for Outcomes Research and Economic Evaluation for Health (C2H); National Institute of Public Health. Summary of cost-effectiveness evaluation of bimekizumab (BIMZELX\u00ae). 2023 Oct 30. Report No.: C2H2203."},{"issue":"3","key":"1788_CR29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s13555-022-00883-y","volume":"13","author":"A Asahina","year":"2023","unstructured":"Asahina A, Okubo Y, Morita A, et al. Bimekizumab efficacy and safety in Japanese patients with plaque psoriasis in BE VIVID: a phase 3, ustekinumab and placebo-controlled study. Dermatol Ther (Heidelb). 2023;13(3):751\u201368.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1788_CR30","unstructured":"Slim M, Kazmierska P, Betts M, Fahrbach K, Neupane B. BKZ report for short-term PASI, economic, and humanistic outcomes: systematic literature review and network meta-analysis of treatments for moderate-to-severe plaque psoriasis. 2022."},{"key":"1788_CR31","doi-asserted-by":"crossref","unstructured":"Batta S, Khan R, Zaayman M, Limmer A, Kivelevitch D, Menter A. IL-17 and -23 inhibitors for the treatment of psoriasis. EMJ Allergy Immunol. 2023.","DOI":"10.33590\/emjallergyimmunol\/10301362"},{"key":"1788_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.814938","volume":"8","author":"D Zhang","year":"2022","unstructured":"Zhang D, Qiu J, Liao X, et al. Comparison of efficacy of anti-interleukin-17 in the treatment of psoriasis between Caucasians and Asians: a systematic review and meta-analysis. Front Med (Lausanne). 2022;8:814938.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"1788_CR33","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/bjd\/ljad429","volume":"190","author":"KB Gordon","year":"2024","unstructured":"Gordon KB, Langley RG, Warren RB, et al. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. Br J Dermatol. 2024;190(4):477\u201385.","journal-title":"Br J Dermatol"},{"issue":"10198","key":"1788_CR34","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Thaci D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576\u201386.","journal-title":"Lancet"},{"issue":"3","key":"1788_CR35","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/bjd.18232","volume":"182","author":"K Reich","year":"2020","unstructured":"Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020;182(3):605\u201317.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1788_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40264-023-01361-w","volume":"47","author":"B Strober","year":"2024","unstructured":"Strober B, Coates LC, Lebwohl MG, et al. Long-term safety of guselkumab in patients with psoriatic disease: an integrated analysis of eleven phase II\/III clinical studies in psoriasis and psoriatic arthritis. Drug Saf. 2024;47(1):39\u201357.","journal-title":"Drug Saf"},{"issue":"5","key":"1788_CR37","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jaad.2024.05.085","volume":"91","author":"S Sood","year":"2024","unstructured":"Sood S, Rimke A, Rankin BD, et al. Real-world experience of bimekizumab for adult patients with plaque psoriasis: a 52-week multicenter retrospective study. J Am Acad Dermatol. 2024;91(5):936\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1788_CR38","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40265-024-02028-1","volume":"84","author":"SE Thomas","year":"2024","unstructured":"Thomas SE, Barenbrug L, Hannink G, Seyger MMB, de Jong EMGJ, van den Reek JMPA. Drug survival of IL-17 and IL-23 inhibitors for psoriasis: a systematic review and meta-analysis. Drugs. 2024;84(5):565\u201378.","journal-title":"Drugs"},{"key":"1788_CR39","unstructured":"Director-General for Statistics, Information Policy and Industrial Relations. Abridged life tables for Japan 2021. Tokyo, Japan: Ministry of Health, Labour and Welfare."},{"key":"1788_CR40","unstructured":"Janssen Pharmaceutical K.K. Pharmaceutical interview form for Tremfya subcutaneous injection. [updated Dec 2021, 6th edition] https:\/\/www.pmda.go.jp\/PmdaSearch\/rdDetail\/iyaku\/3999446G1021_1?user=1"},{"issue":"6","key":"1788_CR41","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","volume":"156","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649\u201358.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"1788_CR42","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/1346-8138.14941","volume":"46","author":"M Ohtsuki","year":"2019","unstructured":"Ohtsuki M, Fujita H, Watanabe M, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2\/3 trial. J Dermatol. 2019;46(8):686\u201394.","journal-title":"J Dermatol"},{"key":"1788_CR43","doi-asserted-by":"crossref","unstructured":"Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50\u20139.","DOI":"10.1111\/bjd.19341"},{"key":"1788_CR44","unstructured":"SUN Pharma Japan Limited. Pharmaceutical interview form for Ilumya subcutaneous injection. [updated Jul 2022, 4th edition] https:\/\/www.pmda.go.jp\/PmdaSearch\/rdDetail\/iyaku\/3999456G1025_1?user=1"},{"key":"1788_CR45","unstructured":"Kyowa Kirin Co. L. Pharmaceutical interview form for Lumicef subcutaneous injection. [updated Nov 2025, 9th edition] https:\/\/www.pmda.go.jp\/PmdaSearch\/rdDetail\/iyaku\/3999441G1029_1?user=1"},{"key":"1788_CR46","unstructured":"National Printing Bureau. Official Gazette Online. https:\/\/kanpou.npb.go.jp\/. Accessed May 2023"},{"key":"1788_CR47","unstructured":"Center for Outcomes Research and Economic Evaluation for Health (C2H); National Institute of Public Health. Guideline for preparing cost-effectiveness evaluation to the Central Social Insurance Medical Council. 2024."},{"issue":"1","key":"1788_CR48","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jval.2019.10.005","volume":"23","author":"M Hasegawa","year":"2020","unstructured":"Hasegawa M, Komoto S, Shiroiwa T, Fukuda T. Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system. Value Health. 2020;23(1):43\u201351.","journal-title":"Value Health"},{"issue":"1","key":"1788_CR49","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/13696998.2018.1532905","volume":"22","author":"A Igarashi","year":"2018","unstructured":"Igarashi A, Igarashi A, Graham CN, Gilloteau I, Tani Y. Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective. J Med Econ. 2018;22(1):7\u201315.","journal-title":"J Med Econ"},{"issue":"1","key":"1788_CR50","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/09546634.2020.1744505","volume":"33","author":"H Saeki","year":"2022","unstructured":"Saeki H, Ishii K, Joshi A, Bensimon AG, Yang H, Kawaguchi I. An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan. J Dermatolog Treat. 2022;33(1):229\u201339.","journal-title":"J Dermatolog Treat"},{"issue":"11","key":"1788_CR51","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1007\/s13555-024-01302-0","volume":"14","author":"RB Warren","year":"2024","unstructured":"Warren RB, Donnelly K, Kiri S, et al. Long-term efficacy and safety of bimekizumab and other biologics in moderate to severe plaque psoriasis: updated systematic literature review and network meta-analysis. Dermatol Ther (Heidelb). 2024;14(11):3133\u201347.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1788_CR52","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1080\/13696998.2023.2259609","volume":"26","author":"V Sigurdardottir","year":"2023","unstructured":"Sigurdardottir V, Engstrom A, Berling P, et al. Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden. J Med Econ. 2023;26(1):1190\u2013200.","journal-title":"J Med Econ"},{"issue":"2","key":"1788_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19020530","volume":"19","author":"MA Boutet","year":"2018","unstructured":"Boutet MA, Nerviani A, Gallo Afflitto G, Pitzalis C. Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int J Mol Sci. 2018;19(2):530.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1788_CR54","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s40273-024-01428-1","volume":"42","author":"IC Antonazzo","year":"2024","unstructured":"Antonazzo IC, Gribaudo G, La Vecchia A, et al. Cost and cost effectiveness of treatments for psoriatic arthritis: an updated systematic literature review. Pharmacoeconomics. 2024;42(12):1329\u201343.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1788_CR55","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/13696998.2016.1219359","volume":"20","author":"AS Pickard","year":"2017","unstructured":"Pickard AS, Gooderham M, Hartz S, Nicolay C. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis. J Med Econ. 2017;20(1):19\u201327.","journal-title":"J Med Econ"},{"key":"1788_CR56","doi-asserted-by":"crossref","unstructured":"Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess. 2006;10(46).","DOI":"10.3310\/hta10460"},{"issue":"1","key":"1788_CR57","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13555-022-00843-6","volume":"13","author":"C Yu","year":"2023","unstructured":"Yu C, Wang G, Burge RT, et al. Outcomes of biologic use in Asian compared with non-Hispanic White adult psoriasis patients from the CorEvitas psoriasis registry. Dermatol Ther (Heidelb). 2023;13(1):187\u2013206.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"1788_CR58","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40273-020-00915-5","volume":"38","author":"M Paulden","year":"2020","unstructured":"Paulden M. Why it\u2019s time to abandon the ICER. Pharmacoeconomics. 2020;38(8):781\u20134.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1788_CR59","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372.","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01788-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T05:02:52Z","timestamp":1781758972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01788-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1788"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01788-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Atsuyuki Igarashi: speaker honoraria from AbbVie, Celgene, Eisai, Eli Lilly, Janssen, Kyowa Kirin, Maruho, Novartis, and Torii Pharmaceutical; research grants from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, LEO Pharma, and UCB. Koichi Shiraishi, Yukihiko Iizuka, Eiko Yamamura, and Masakazu Hase: employees of UCB. Shota Saito: employee of CRECON Medical Assessment Inc. at the time of the study and during manuscript preparation; he is currently employed by the University of Niigata Prefecture and employment began during preparation of the manuscript. Tomoya Kudo: employee of CRECON Medical Assessment Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not require ethical approval, as the analyses performed were based on mathematical modeling with inputs extracted from existing literature or unpublished, aggregated data. All data referenced were anonymized and contained no personal information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}